# Merit Medical acquires Biolife Delaware for $120M

Merit Medical Systems acquired Biolife Delaware, a manufacturer of hemostatic devices, for approximately $120 million in cash and assumed liabilities. The acquisition adds the StatSeal and WoundSeal product lines to Merit's portfolio.

- Type: Acquisition
- Announced: 2025-05-20
- Where: South Jordan, Utah (Merit HQ); Sarasota, Florida (Biolife HQ), United States
- Value: $120.0M
- Status: completed
- Products: hemostatic devices, StatSeal, WoundSeal
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Merit Medical Systems](https://endata.com/companies/28214.md) (acquirer)
- [Biolife Delaware](https://endata.com/companies/84859.md) (target)

## Sources

- [barchart.com](https://www.barchart.com/press-releases/32483270/merit-medical-acquires-biolife-delaware-l-l-c), 2025-05-20: "We are excited to enhance the portfolio of hemostatic solutions offered to clinicians with the acquisition of Biolife."
- [mddionline.com](https://www.mddionline.com/ma/merit-medical-seals-the-deal-with-biolife-merger), 2025-05-20: "We are excited to enhance the portfolio of hemostatic solutions offered to clinicians with the acquisition of Biolife."
- [interventionalnews.com](https://interventionalnews.com/merit-medical-acquires-haemostatic-device-manufacturer-biolife/), 2025-05-21: "This strategic acquisition positions Merit to provide clinicians with more products designed to standardise, simplify, and minimise post-procedure care and maintenance."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.